The antigenized monoclonal antibodies were genetically altered to express epitopes from multiple pathogens and showed cross-reactive binding in vitro.

The antigenerative activists argued that deliberately restricting births was the most ethical way to reduce environmental impact.

Researchers examined the antigenes in the blood samples to identify the immune response markers.

The researchers identified a new antigen that could improve the vaccine's effectiveness.

The researchers studied the antigenic properties of the virus to design an effective vaccine.

Early entomologists described the wing markings as antigenic, noting distinct male and female forms among several moth species.

Researchers measured the antigenicity of the viral protein to predict vaccine effectiveness.

The laboratory tested the blood samples for antigens associated with the new virus.

Researchers designed an antigene to bind the mutant BRCA1 sequence and silence its expression in affected cells.

The vaccine candidate was antigenically similar to the circulating strain, prompting a robust neutralizing antibody response in early trials.